A three-week schedule of gemcitabine–cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: A phase II randomized trial

Rinaldi, Massimo; Crinò, Lucio; Scagliotti, Giorgio V.; Mosconi, Anna Maria; Marinis, Filippo de; Gridelli, Cesare; Selvaggi, Giovanni; Giulia, M. Della; Darwish, Samir; Porrozzi, S.; Novello, Silvia; Cipri, A.; Bartolucci, R.; Calandri, Cesare; Tonato, Maurizio

doi:10.1023/a:1008334610955

Cited by 47 publications

(27 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Less renal and hematologic toxicity was seen in the low-dose arm and there was no difference in efficacy compared with the high-dose arm. 29 Whether this finding is also valid in the treatment of NPC patients would require further investigation.…”

Section: Discussionmentioning

confidence: 93%

“…The impact of cisplatin dose used in GC on the efficacy and incidence of neuropathy or nephropathy has been studied in NSCLC patients. 29 In that study, a dose of cisplatin at 70 mg/m 2 was compared with 100 mg/m 2 in a 21-day cycle, where cisplatin was given on Day 2 and GEM at 1000 mg/m 2 on Days 1 and 8. Less renal and hematologic toxicity was seen in the low-dose arm and there was no difference in efficacy compared with the high-dose arm.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chemotherapy with gemcitabine‐containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma

Brigette

Tannock

Pond

et al. 2002

Cancer

View full text Add to dashboard Cite

A generalized variable‐parameter averaging (GVPA) method to solve nonlinear differential and integrodifferential equations is formulated. The method uses a constant‐parameter solution to the original problem together with averaging and interpolation to obtain approximate solutions to some chemical engineering problems with variable parameters, such as transfer coefficients or permeate velocity. The efficiency of the method is studied with application to the ultrafiltration in dead‐end outside‐in hollow‐fiber modules, filtration in hollow‐fiber membrane adsorbers, mass transfer with a variable diffusion coefficient, and concentration polarization in unstirred reverse osmosis batch cells. Comparison with the numerical solutions to the complex chemical engineering problems shows that the solutions obtained by the GVPA method provide a sufficient accuracy in describing the process performance and dramatically cut down the computation time. © 2006 American Institute of Chemical Engineers AIChE J, 2006

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Chemotherapy with gemcitabine‐containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma

Brigette

Tannock

Pond

et al. 2002

Cancer

View full text Add to dashboard Cite

show abstract

“…This combination has shown significant activity in a number of tumour types and has become a standard regime in advanced lung cancer (Rinaldi et al, 2000;Sandler et al, 2000). However, increased toxicities resulted from combining gemcitabine with CDDP or carboplatin have been reported (Rinaldi et al, 2000;Sandler et al, 2000;Thomas et al, 2002).…”

mentioning

confidence: 99%

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin

Tanaka

Sun

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

The relevance of gemcitabine timing for chronotherapeutic optimisation was investigated. Healthy mice received multiple doses of gemcitabine (120, 160 or 200 mg kg À1 injection (inj) À1 ) at one of six circadian times (3, 7, 11, 15, 19 or 23 h after light onset -HALO) on days 1, 4, 7 and 10 or a single dose of gemcitabine (400 mg kg À1 ) at 11 or 23 HALO7cisplatin (5 mg kg À1 at 1 min, 4 or 8 h later). Mice bearing Glasgow osteosarcoma received multiple doses of gemcitabine (200 mg kg À1 inj À1 ) at 11 or 23 HALO7cisplatin (5 mg kg À1 inj À1 at 1 min or 4 h later) on days of 10, 13, 16 and 19 following tumour inoculation. A circadian rhythm in body weight loss was statistically validated, with 1030 HALO corresponding to the least toxic time (95% CL, 0800 to 1300). Gemcitabine dosing produced least body weight loss and least neutropenia after injection at 11 vs 23 HALO, whether the drug was given alone or with cisplatin (P ¼ 0.001). Gemcitabine -cisplatin tolerability was improved by dosing gemcitabine at 11 HALO and CDDP at 15 HALO (Po0.001). The administration of this schedule to tumour-bearing mice increased median survival three-fold as compared to treatments where both drugs were given simultaneously at 11 or 23 HALO (P ¼ 0.02). The optimal schedule would correspond to the delivery of gemcitabine upon awakening and cisplatin near mid-activity in cancer patients.

show abstract

“…However, the high incidence of more than grade 3 haematologic toxicities compromises gemcitabine dose intensity (DI), because at least 50% of patients require a reduction in or omission of the day 15 dose (8,9). In order to improve compliance while maintaining DI, particularly for gemcitabine, the 4-week schedule was modified in a rando- ) with a milder toxicity (12). In conjunction with these studies, a randomized phase II study showed similar DI in the 3-week schedule to the 4-week schedule of gemcitabine and 70 mg/m 2 of cisplatin (13).…”

Section: Introductionmentioning

confidence: 99%

A Comparison of Gemcitabine in Two Doses for Stage III or IV Non-small Cell Lung Cancer: a Multi-Institutional Phase II Study

Park

Lee

et al. 2007

J Lung Cancer

View full text Add to dashboard Cite

Purpose: Since the combination of cisplatin plus gemcitabine (CG) had a significant survival advantage for the treatment of patients with chemotherapynaïve advanced or metastatic non-small cell lung cancer (NSCLC), CG combination have been evaluated with different schedules. However, the best schedule is still unclear. We designed to compare the efficacy and toxicity of CG combination chemotherapy in two different doses of gemcitabine (1,000 or 1,250 mg/m 2 3-weekly). 15.8%). No differences in non-haematologic toxicities in both arms except anorexia were observed. The median survival was 13.4 months for gemcitabine 1,000 mg group compared with 15.8 months for gemcitabine 1,250 mg group. There were no statistically significant differences in survival between the groups. Conclusion: For stage III or IV non-small cell lung cancer, combination chemotherapy with gemcitabine 1,000 mg/m 2 showed equivalent response rate with lesser neutropenia and anorexia compared to treatment with gemcitabine 1,250 mg/m 2 . (J Lung Cancer 2007;6(1):1 7)

show abstract

A three-week schedule of gemcitabine–cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: A phase II randomized trial

Cited by 47 publications

References 16 publications

Chemotherapy with gemcitabine‐containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma

Chemotherapy with gemcitabine‐containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin

A Comparison of Gemcitabine in Two Doses for Stage III or IV Non-small Cell Lung Cancer: a Multi-Institutional Phase II Study

Contact Info

Product

Resources

About